Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
401 people get OGXI articles and Market Currents by email alert.
Get email alerts on OGXI »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (Apr 23, 2013)
-
-
PR Newswire (Mar 28, 2013)
-
-
-
-
PR Newswire (Feb 5, 2013)
-
-
PR Newswire (Nov 9, 2012)
-
-
-
-
Playing OncoGenex's ASCO DataJessica King Holden • Mon, Jun 4, 2012 -
OncoGenex Pharmaceuticals: Novel Products, Financial FlexibilityJason Chew • Wed, Dec 15, 2010
-
-
-
-
3 Healthcare Stocks With Strong Buy Analyst Ratings And Minimal DebtZetaKap • Thu, Aug 23, 2012 -
-
-
-
-
-
-
-
-
-
-
-
-
-
Life Technologies Could Open Doors For PharmaceuticalsJessica King Holden • Thu, Jan 12, 2012
-
-
-
OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptMon, May 10, 2010
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Mar 28, 2013)
-
PR Newswire (Feb 5, 2013)
-
at MarketWatch.com (Jan 2, 2013)
-
PR Newswire (Nov 9, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Oct 30, 2012)
-
PR Newswire (Sep 27, 2012)
-
PR Newswire (Aug 28, 2012)
OGXI vs. ETF Alternatives
Company Description
Currently, there's no company description for OGXI.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, March 7, 5:14 PM OncoGenex Pharmaceuticals (OGXI): Q4 EPS of -$0.28 beats by $0.22. Revenue of $9.8M beats by $2.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, February 12, 1:14 PM OncoGenex Pharmaceuticals (OGXI +1.4%) trades up today after saying it's initiating Phase 2 clinical studies to evalutate OGX-427, a treatment for patients with advanced metastatic bladder cancer. The study is sponsored by Hoosier Oncology Group. Comment! [Healthcare, On the Move]
- Monday, February 4, 6:48 PM OncoGenex Pharmaceuticals (OGXI) says that CFO Michelle Burris has resigned that position after she and CEO Scott Cormack told the board last month about a developing personal relationship, which spurred directors to seek a transfer of executive duties. She'll serve as EVP of operations until March 31 and act as a consultant to the firm over the next year; the board tapped Cormack as Principal Financial Officer, Secretary and Treasurer, replacing Burris in those roles. Shares -3.4% AH. Comment! [Healthcare, On the Move]
- Friday, March 16, 2012, 9:39 AM OncoGenex Pharmaceuticals (OGXI -18.9%) dives after stating the share offering announced yesterday will involve selling 4.165M shares at a price of just $12. Even after today's crash, OncoGenex shares are changing hands at $14.47. Comment! [Healthcare, On the Move]
- Thursday, March 15, 2012, 4:23 PM OncoGenex Pharmaceuticals (OGXI +7.6%) falls 12.3% AH after filing for a stock offering featuring an undisclosed number of shares. The company plans to partly use the proceeds to develop its OGX-427 cancer drug, and possibly other drug candidates. Comment! [Healthcare, On the Move]
- Friday, August 5, 2011, 1:33 PM Shares of OncoGeneX (OGXI -24.3%) crater after the firm announces two of its drug-development programs for lung cancer will have delayed results. Interestingly, the share price started falling yesterday in advance of this morning's announcement. 1 Comment [On the Move, Healthcare]
-
Tuesday, October 19, 2010, 9:15 AM
Premarket gainers: CTIC +14%. MEE +10%. PH +9%. RNN +7%.
Losers: INFN -33%. CWTR -29%. OGXI -15%. KCI -13%. BXC -11%. HT -7%. BKCC -7%. NVO -7%. VMW -7%. AIB -6%. ABK -5%. RIO -5%. ALU -5%. AAPL -5%. HL -4%. IBM -4%. RCL -4%. AUY -4%. ARMH -4%. WFT -4%. BHP -4%. SLW -4%. TOT -4%. Comment! -
Monday, December 21, 2009, 9:00 AM
Premarket gainers: CHTT +33%. TEX +9%. BUCY +8%. INCY +6%. CTIC +5%. BCRX +4%. ABK +4%. AA +4%. CAG +4%.
Losers: OGXI -21%. IRE -9%. GIGM -7%. AIB -6%. LYG -5%. Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.